Edition:
India

Becton Dickinson and Co (BDX.N)

BDX.N on New York Stock Exchange

224.08USD
25 Sep 2020
Change (% chg)

$2.92 (+1.32%)
Prev Close
$221.16
Open
$220.05
Day's High
$224.57
Day's Low
$219.50
Volume
363,042
Avg. Vol
513,845
52-wk High
$286.67
52-wk Low
$197.75

Latest Key Developments (Source: Significant Developments)

Bd Announces FDA Classifications For August 4Th Recalls Of BD Alaris System
Monday, 21 Sep 2020 

Sept 21 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES FDA CLASSIFICATIONS FOR AUGUST 4TH RECALLS OF BD ALARIS™ SYSTEM HARDWARE FOR KEYPADS, INCORRECT MODULE TYPES AND/OR SIZES, AND CHANNEL ERROR.BECTON DICKINSON AND CO - THREE RECALLS DESIGNATED AS CLASS I BY FDA; ONE DESIGNATED AS CLASS II.  Full Article

U.S. FDA Alerts Clinical Lab Staff,Health Care Providers Of Increased Risk Of False Positive Result With BD SARS-CoV-2 Reagents For BD Max System Test
Tuesday, 7 Jul 2020 

July 6 (Reuters) - :U.S. FDA ALERTS CLINICAL LAB STAFF,HEALTH CARE PROVIDERS OF INCREASED RISK OF FALSE POSITIVE RESULT WITH BD SARS-COV-2 REAGENTS FOR BD MAX SYSTEM TEST.U.S. FDA IS WORKING WITH BECTON, DICKINSON AND CO TO RESOLVE FALSE POSITIVE RESULTS WITH BD SARS-COV-2 REAGENTS FOR BD MAX SYSTEM ISSUE.  Full Article

FDA Statement On Concerns With Medical Device Availability Due To Certain Sterilization Facility Closures
Friday, 25 Oct 2019 

Oct 25 (Reuters) - U.S. Food and Drug Administration::U.S. FOOD AND DRUG ADMINISTRATION STATEMENT ON CONCERNS WITH MEDICAL DEVICE AVAILABILITY DUE TO CERTAIN STERILIZATION FACILITY CLOSURES.FDA SAYS AGAIN ALERTING PUBLIC TO GROWING CONCERNS ABOUT FUTURE AVAILABILITY OF STERILE MEDICAL DEVICES AND IMPENDING MEDICAL DEVICE SHORTAGES.FDA - POTENTIAL CLOSURE OF LARGE BECTON DICKINSON STERILIZATION FACILITY IN GEORGIA MAY AFFECT AVAILABILITY OF SOME STERILE MEDICAL DEVICES.FDA - RECOGNIZES THERE ARE CONCERNS ASSOCIATED WITH RELEASE OF ETHYLENE OXIDE INTO ENVIRONMENT IF EMISSIONS WERE TO OCCUR AT UNSAFE LEVELS.FDA - MONITORING SUPPLY CHAIN EFFECTS OF CLOSURES, POTENTIAL CLOSURES OF SOME STERILIZATION FACILITIES USING ETHYLENE OXIDE TO STERILIZE MEDICAL DEVICES .FDA - THERE ARE NO READILY AVAILABLE PROCESSES, FACILITIES TO SERVE AS VIABLE ALTERNATIVES TO THOSE USING ETHYLENE OXIDE TO STERILIZE DEVICES.FDA - ANTICIPATE NATIONAL SHORTAGE OF MEDICAL DEVICES MADE FROM CERTAIN POLYMERS, METALS OR GLASS THAT ARE LIKELY TO BE STERILIZED WITH ETHYLENE OXIDE.FDA SAYS ARE URGING MEDICAL DEVICE MANUFACTURERS THAT USE ETHYLENE OXIDE FACILITIES TO ASSESS THEIR INVENTORY.FDA SAYS WORKING WITH MEDICAL DEVICE MANUFACTURERS TO LOOK FOR ALTERNATIVE STERILIZATION OPTION.  Full Article

Becton Dickinson And Co Sets Quarterly Dividend Of $0.77 Per Share
Tuesday, 23 Jul 2019 

July 22 (Reuters) - Becton Dickinson and Co ::SETS QUARTERLY DIVIDEND OF $0.77PER SHARE.  Full Article

FDA Says Becton Dickinson & Company Recalls SmartSite Syringe Administration Set Due To Risk Of Leaks
Tuesday, 2 Jul 2019 

July 1 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS BECTON DICKINSON & COMPANY RECALLS SMARTSITE SYRINGE ADMINISTRATION SET DUE TO RISK OF LEAKS.U.S. FDA SAYS HAS IDENTIFIED BECTON DICKINSON'S RECALL OF THE SMARTSITE SYRINGE ADMINISTRATION SET AS A CLASS I RECALL.U.S. FDA SAYS BECTON DICKINSON RECALLED 2,900 SMARTSITE SYRINGE ADMINISTRATION SETS IN THE U.S; BECTON DICKINSON INITIATED RECALL ON FEB 22, 2019.U.S. FDA SAYS BECTON DICKINSON HAS NOT RECEIVED ANY REPORTS OF SERIOUS INJURY OR DEATH DUE TO MALFUNCTION OF SMARTSITE SYRINGE ADMINISTRATION SET.  Full Article

BD Gets FDA Approval For First Venous Stent
Thursday, 14 Mar 2019 

March 14 (Reuters) - Becton Dickinson and Co ::BD RECEIVES U.S. FDA APPROVAL FOR FIRST VENOUS STENT TO TREAT ILIOFEMORAL VENOUS OCCLUSIVE DISEASE.BECTON DICKINSON AND CO - VENOVO VENOUS STENT PROVEN SAFE AND EFFECTIVE IN ILIAC AND FEMORAL VEINS.  Full Article

UK Regulator Says No Safety Concerns On Recall Of C.R. Bard's Urogynaecological Mesh
Thursday, 7 Mar 2019 

March 7 (Reuters) - UK's Medicines And Healthcare Products Regulatory Agency: :UK'S MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MEDICAL DEVICE ALERT ISSUED FOR UROGYNAECOLOGICAL MESH MANUFACTURED BY C.R. BARD.UK'S MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY - ALERT ISSUED ON C.R. BARD REMOVING VAGINAL MESH FOR SUI, PELVIC ORGAN PROLAPSE FROM MARKET.UK'S MEDICINES & HEALTHCARE PRODUCTS REGULATORY AGENCY - NO SPECIFIC SAFETY CONCERNS ASSOCIATED WITH RECALL OF C.R. BARD'S UROGYNAECOLOGICAL MESH.  Full Article

Becton Dickinson and Co Sees Q1 EPS Of $2.05
Thursday, 17 Jan 2019 

Jan 17 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES PRELIMINARY RESULTS FOR 2019 FIRST FISCAL QUARTER; REAFFIRMS FISCAL 2019 GUIDANCE.SEES Q1 EARNINGS PER SHARE ABOUT $2.05.Q1 PRELIMINARY EARNINGS PER SHARE $2.05.Q1 EARNINGS PER SHARE ESTIMATE $2.61 -- REFINITIV IBES DATA.SEES FY 2019 ADJUSTED EARNINGS PER SHARE $12.05 TO $12.15.Q1 PRELIMINARY ADJUSTED EARNINGS PER SHARE $2.70.SEES FY 2019 REVENUE UP 8.5 TO 9.5 PERCENT.Q1 REVENUE $4.16 BILLION VERSUS REFINITIV IBES ESTIMATE OF $4.11 BILLION.SEES Q1 2019 REVENUE $4.16 BILLION.REAFFIRMS PREVIOUSLY ISSUED FISCAL YEAR 2019 REVENUE AND ADJUSTED DILUTED EPS GUIDANCE.Q1 EARNINGS PER SHARE VIEW $2.61, REVENUE VIEW $4.11 BILLION -- REFINITIV IBES DATA.FY2019 EARNINGS PER SHARE VIEW $12.12, REVENUE VIEW $17.43 BILLION -- REFINITIV IBES DATA.  Full Article

Becton, Dickinson And Co Sets Quarterly Dividend Of $0.77 Per Share
Tuesday, 20 Nov 2018 

Nov 19 (Reuters) - Becton Dickinson and Co ::SETS QUARTERLY DIVIDEND OF $0.77PER SHARE.SAYS DIVIDEND REPRESENTS INCREASE OF 2.7 PERCENT FROM PREVIOUS QUARTER.  Full Article

Becton Dickinson Announces Clinical Trial Data For The Lutonix 014 DCB
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Becton Dickinson and Co ::BD ANNOUNCES CLINICAL TRIAL DATA FOR THE LUTONIX® 014 DRUG-COATED BALLOON BELOW-THE-KNEE IDE TRIAL.BECTON DICKINSON - STUDY'S PRIMARY SAFETY ENDPOINT WAS MET SHOWING STATISTICALLY SIGNIFICANT SAFETY EQUIVALENCE BETWEEN LUTONIX 014 DCB & STANDARD PTA CATHETER.  Full Article

Photo

French labs show how global supply bottlenecks thwart effort to ramp up testing

PARIS Mass testing was meant to be the answer to the second wave. Politicians promised that with enough tests, conducted quickly enough, they could keep the coronavirus in check, without having to resort to lockdowns that crippled economies six months ago.